Genome-wide DNA methylation profiling identifies ALDH1A3 promoter methylation as a prognostic predictor in G-CIMP- primary glioblastoma

Cancer Letters

Volumn 328, Issue 1, 2013, Pages 120-125

  Zhang, Wei ^a   Yan, Wei ^a   You, Gan ^a   Bao, Zhaoshi ^a   Wang, Yongzhi ^a   Liu, Yanwei ^a   You, Yongping ^b   Jiang, Tao ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

DNA methylation; G CIMP; IDH1 mutation; Primary glioblastoma; Prognosis

Indexed keywords

ALDEHYDE DEHYDROGENASE; ALDEHYDE DEHYDROGENASE 1A3; DNA; ISOCITRATE DEHYDROGENASE 1; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ARTICLE; CANCER PROGNOSIS; CANCER SURVIVOR; CANCER TISSUE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; FEMALE; GENE LOCUS; GENE MUTATION; GENETIC ASSOCIATION; GENOME ANALYSIS; GLIOBLASTOMA; GLIOMA CPG ISLAND METHYLATOR PHENOTYPE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; NEUROSURGERY; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PYROSEQUENCING; SURVIVAL TIME;

DNA FINGERPRINTING; DNA METHYLATION; FEMALE; GENOME-WIDE ASSOCIATION STUDY; GLIOBLASTOMA; HUMANS; ISOENZYMES; MALE; PROGNOSIS; PROMOTER REGIONS, GENETIC; RETINAL DEHYDROGENASE; TUMOR MARKERS, BIOLOGICAL;

EID: 84868446084     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.08.033     Document Type: Article

References (19)

1. Krex D., Klink B., Hartmann C., von Deimling A., Pietsch T., Simon M., Sabel M., Steinbach J.P., Heese O., Reifenberger G., Weller M., Schackert G. Long-term survival with glioblastoma multiforme. Brain 2007, 130:2596-2606.
2. Weller M., Stupp R., Reifenberger G., Brandes A.A., van den Bent M.J., Wick W., Hegi M.E. MGMT promoter methylation in malignant gliomas: ready for personalized medicine?. Nat. Rev. Neurol. 2010, 6:39-51.
3. Christensen B.C., Smith A.A., Zheng S., Koestler D.C., Houseman E.A., Marsit C.J., Wiemels J.L., Nelson H.H., Karagas M.R., Wrensch M.R., Kelsey K.T., Wiencke J.K. DNA methylation, isocitrate dehydrogenase mutation, and survival in glioma. J. Natl. Cancer Inst. 2011, 103:143-153.
4. Czernicki T., Zegarska J., Paczek L., Cukrowska B., Grajkowska W., Zajaczkowska A., Brudzewski K., Ulaczyk J., Marchel A. Gene expression profile as a prognostic factor in high-grade gliomas. Int. J. Oncol. 2007, 30:55-64.
5. Freije W.A., Castro-Vargas F.E., Fang Z., Horvath S., Cloughesy T., Liau L.M., Mischel P.S., Nelson S.F. Gene expression profiling of gliomas strongly predicts survival. Cancer Res. 2004, 64:6503-6510.
6. Gravendeel L.A., Kouwenhoven M.C., Gevaert O., de Rooi J.J., Stubbs A.P., Duijm J.E., Daemen A., Bleeker F.E., Bralten L.B., Kloosterhof N.K., De Moor B., Eilers P.H., van der Spek P.J., Kros J.M., Sillevis Smitt P.A., van den Bent M.J., French P.J. Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology. Cancer Res. 2009, 69:9065-9072.
7. Laffaire J., Everhard S., Idbaih A., Criniere E., Marie Y., de Reynies A., Schiappa R., Mokhtari K., Hoang-Xuan K., Sanson M., Delattre J.Y., Thillet J., Ducray F. Methylation profiling identifies 2 groups of gliomas according to their tumorigenesis. Neuro Oncol. 2011, 13:84-98.
8. Lund A.H., van Lohuizen M. Epigenetics and cancer. Genes Dev. 2004, 18:2315-2335.
9. Gaspar-Maia A., Alajem A., Meshorer E., Ramalho-Santos M. Open chromatin in pluripotency and reprogramming. Nat. Rev. Mol. Cell. Biol. 2011, 12:36-47.
10. Noushmehr H., Weisenberger D.J., Diefes K., Phillips H.S., Pujara K., Berman B.P., Pan F., Pelloski C.E., Sulman E.P., Bhat K.P., Verhaak R.G., Hoadley K.A., Hayes D.N., Perou C.M., Schmidt H.K., Ding L., Wilson R.K., Van Den Berg D., Shen H., Bengtsson H., Neuvial P., Cope L.M., Buckley J., Herman J.G., Baylin S.B., Laird P.W., Aldape K. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 2010, 17:510-522.
11. van den Bent M.J., Gravendeel L.A., Gorlia T., Kros J.M., Lapre L., Wesseling P., Teepen J.L., Idbaih A., Sanson M., Smitt P.A., French P.J. A hypermethylated phenotype is a better predictor of survival than MGMT methylation in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. Clin. Cancer Res. 2011, 17:7148-7155.
12. Hill V.K., Ricketts C., Bieche I., Vacher S., Gentle D., Lewis C., Maher E.R., Latif F. Genome-wide DNA methylation profiling of CpG islands in breast cancer identifies novel genes associated with tumorigenicity. Cancer Res. 2011, 71:2988-2999.
13. Yan W., Zhang W., You G., Bao Z., Wang Y., Liu Y., Kang C., You Y., Wang L., Jiang T. Correlation of IDH1 mutation with clinicopathologic factors and prognosis in primary glioblastoma: a report of 118 patients from China. PLoS One 2012, 7:e30339.
14. Zhang W., Qiu X.G., Chen B.S., Li S.W., Cui Y., Ren H., Jiang T. Antiangiogenic therapy with bevacizumab in recurrent malignant gliomas: analysis of the response and core pathway aberrations. Chin. Med. J. (Engl.) 2009, 122:1250-1254.
15. Iacob G., Dinca E.B. Current data and strategy in glioblastoma multiforme. J. Med. Life 2009, 2:386-393.
16. Schatz P., Distler J., Berlin K., Schuster M. Novel method for high throughput DNA methylation marker evaluation using PNA-probe library hybridization and MALDI-TOF detection. Nucleic Acids Res. 2006, 34:e59.
17. Marcato P., Dean C.A., Giacomantonio C.A., Lee P.W. Aldehyde dehydrogenase: its role as a cancer stem cell marker comes down to the specific isoform. Cell Cycle 2011, 10:1378-1384.
18. Ma S., Chan K.W., Lee T.K., Tang K.H., Wo J.Y., Zheng B.J., Guan X.Y. Aldehyde dehydrogenase discriminates the CD133 liver cancer stem cell populations. Mol. Cancer Res. 2008, 6:1146-1153.
19. Moreb J.S. Aldehyde dehydrogenase as a marker for stem cells. Curr. Stem Cell Res. Ther. 2008, 3:237-246.